Mike Hollan

Texas filed its lawsuit just days before Kennedy made his remarks.

The company will no longer be spinning CSL Seqirus next June.

Marcel Botha, CEO of 10XBeta, discusses FDA’s new pilot authorization program for abbreviated new drug applications (ANDA) and what impact it will have on manufacturing and the supply chain.

The agency says the new guidelines will simplify the requirements to bring biosimilars to market.

President Trump’s claims about $150 weight-loss medication are causing investors to question the importance of the contents of the current earnings reports.

Chris O’Dell, SVP of market solutions at Turquoise Health, explains why the administration’s efforts aren’t likely to impact generics in the near future.

Marcel Botha, CEO of 10XBeta, discusses FDA’s new pilot authorization program for abbreviated new drug applications (ANDA) and what impact it will have on manufacturing and the supply chain.

Chris O’Dell, SVP of market solutions at Turquoise Health, discusses the impact on the various middle-men involved in drug-pricing.

The group says that willpower alone won’t help most people.

Chris O’Dell, SVP of market solutions at Turquoise Health, details the ways that the President’s new program differs from previous programs.

Researchers reveal that GLP-1 medication Ozempic may reduce biological age, offering new hope in the fight against aging and related health issues.

Chris O’Dell, SVP of market solutions at Turquoise Health, discusses why it's important to a shine a light on this aspect of the healthcare ecosystem.

Chris O’Dell, SVP of market solutions at Turquoise Health, explains the timeline to expect changes to prescription drug prices based on current DTC trend.

Jesse Mendelsohn, executive vice president at Model N, discusses the broader issues impacting drug prices.

Cencora CEO Bob Mauch discusses the lessons learned during his first year at the helm—and tackling a complex future for pharma distribution.

The proposed change would add a warning about an increased risk of autism, despite a lack of scientific evidence connecting the medication to the condition.

The company will hold an Extraordinary General Meeting in November to elect new members.

Jesse Mendelsohn, executive vice president at Model N, explains the pros and cons of continuing to pursue DTC programs once the government-run program launches.

Artax Biopharma’s CEO Rob Armstrong explains recent shifts in autoimmune R&D before discussing his leadership style.

The two companies are the latest to join the DTC offerings to address high drug prices.

Nine medications are on the initial list of program participants.

The President claimed that prices would drop significantly based on government negotiations.

Jesse Mendelsohn, executive vice president at Model N, discusses how selling drugs directly to patients differs from traditional government programs.

As timelines change, medical affairs teams must adjust their skillsets.

Acadia Pharmaceuticals’ CEO Catherine Owen Adams discusses the current climate in R&D and details her leadership style.

Efforts to regulate pharma prices will impact other sectors of healthcare, with PBMs likely to feel the impact.

The current administration’s efforts are just the latest attempt from the government to improve drug prices in the US.

The company’s CEO will reportedly joining the President to announce the deal.

Multiple pharma companies have already announced plans to invest in domestic projects.

As drug prices in the US fluctuate, pharma companies may look to other regions for opportunity.